GDA-201 is under clinical development by Gamida Cell and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GDA-201’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 07 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 07 Nov 2022 increased GDA-201’s LoA and PTSR for Follicular Lymphoma, increased PTSR for Mantle Cell Lymphoma, increased LoA and PTSR for Non-Hodgkin Lymphoma, increased LoA and PTSR for Refractory Multiple Myeloma, and increased LoA and PTSR for Relapsed Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GDA-201 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GDA-201 overview

GDA-201 is under development for the treatment of refractory/relapsed multiple myeloma, B-cell non-Hodgkin lymphoma including diffuse large B cell lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma and follicular lymphoma. The therapeutic candidate is administered as an intravenous infusion. The therapeutic candidate comprises of NK cells. It is developed based on NAM platform technology and editas medicine’s CRISPR technology. The therapeutic candidate was also under development for the treatment of leukemias.

Gamida Cell overview

Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.

Quick View GDA-201 LOA Data

Report Segments
  • Innovator
Drug Name
  • GDA-201
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.